脂蛋白關聯(lián)磷脂酶A2(LpPLA2)活性蛋白
Active Phospholipase A2 Group VII (LpPLA2)
PLA2G7; PAF-AH; PAFAH; Lp-PLA2; LDL-PLA2; Platelet Activating Factor Acetylhydrolase,Plasma; Phospholipase A2,Group VII; LDL-associated phospholipase A2; Phospholipase A2, Lipoprotein Associated
- 編號APA867Hu01
- 物種Homo sapiens (Human，人) 相同的名稱，不同的物種。
- 緩沖液成份PBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
- 性狀凍干粉
- 純度> 90%
- 等電點7.1
- 應用Cell?culture;?Activity?Assays.
- 下載 英文說明書 中文說明書
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價格 ¥ 1584 ¥ 3960 ¥ 7920 ¥ 23760 ¥ 59400
- 欲了解實際交易價格和更多情況，請與當地經銷商聯(lián)系!
-
產品包裝(模擬)
-
產品包裝(模擬)
-
Figure. Gene Sequencing (Extract)
-
Figure. SDS-PAGE
-
WB圖
-
通過ISO 9001、ISO 13485質量體系認證
活性實驗
Phospholipase A2 Group VII (PLA2G7) which is also known as Lp-PLA2, is a plasma enzyme bound to lipoproteins: 80% bound to LDL, 15%-20% to HDL, and the remainder to VLDL. It is produced in major by mature macrophages and activated platelets and?catalyzes the degradation of platelet-activating factor to biologically inactive products. Besides, Paraoxonase 1 (PON1) has been identified as an interactor of PLA2G7, thus a functional binding ELISA assay was conducted to detect the interaction of recombinant human PLA2G7 and recombinant rat PON1. Briefly, PLA2G7 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 ul were then transferred to PON1-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-PLA2G7 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50μL stop solution to the wells and read at 450/630 nm immediately. The binding activity of recombinant human PLA2G7 and recombinant rat PON1 was shown in Figure 1, the EC50?for this effect is 0.7 ug/mL.
用法
Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
儲存
避免反復凍融。2-8°C不超過一個月，-80°C不超過12個月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗決定，具體方法如下：在37°C孵育48小時，沒有顯著的降解或者沉淀產生。保質期內，在適當的條件下存儲，損失率低于5%。
增值服務
相關產品
| 編號 | 適用物種：Homo sapiens (Human，人) | 應用(僅供研究使用，不用于臨床診斷！) |
| RPA867Hu02 | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA867Hu03 | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| RPA867Hu04 | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| APA867Hu01 | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)活性蛋白 | Cell?culture;?Activity?Assays. |
| RPA867Hu01 | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| PAA867Hu01 | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)多克隆抗體 | WB; IHC; ICC; IP. |
| LAA867Hu81 | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)多克隆抗體(異硫氰酸熒光素標記) | WB; IHC; ICC; IF. |
| LAA867Hu71 | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)多克隆抗體(生物素標記) | WB; IHC; ICC. |
| MAA867Hu21 | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)單克隆抗體 | WB; IHC; ICC; IP. |
| MAA867Hu22 | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)單克隆抗體 | WB; IHC; ICC; IP. |
| SEA867Hu | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)檢測試劑盒(酶聯(lián)免疫吸附試驗法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| SCA867Hu | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)檢測試劑盒(化學發(fā)光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
| LMA867Hu | 脂蛋白關聯(lián)磷脂酶A2(LpPLA2)等多因子檢測試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻
| 雜志 | 參考文獻 |
| Science & Sports | The effects of different intensity walking programs on serum blood lipids, high-sensitive C-reactive protein, and lipoprotein-associated phospholipase A2 in premenopausal women [ScienceDirect: S0765159710000262] |
| Metabolic Syndrome and Related Disorders | Association of Serum Lipoprotein-Associated Phospholipase A2 Level with Nonalcoholic Fatty Liver Disease [Wiley: source] |
| 34 | Effects of Pycnogenol on endothelial function in patients with stable coronary artery disease: a double-blind, randomized, placebo-controlled, cross-over study [PubMed: 22240497] |
| PLoS ONE | Effects of Lipid-Lowering Drugs on Irisin in Human Subjects In Vivo and in Human Skeletal Muscle Cells Ex Vivo [PubMed: PMC3759413] |
| China Pharmacy | Influence of Tongfengtai Granules on Inflammatory Factor in Acute Gouty Arthritis Model Rats [Source] |
| Atherosclerosis | Everolimus therapy is associated with reduced lipoprotein-associated phospholipase A2 (Lp-Pla2) activity and oxidative stress in heart transplant recipients. [Pubmed: 23958269] |
| Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus [Hindawi: 278063] |
| Health | The Role of Asymmetric Dimethylarginine and Lipoprotein Associated Phospholipase A2 in Children and Adolescents with Dyslipidemia [Scirp:Source] |
| Biology Bulletin | In vitro lipid-lowering and fibrinolytic effects of regulatory leucine-containing glyprolines in human blood [Springer:Source] |
| Gynecol Endocrinol. | Lipoprotein-associated phospholipase A2 and AGEs are associated with cardiovascular risk factors in women with history of gestational diabetes mellitus. [Pubmed:24397392] |
| Journal of Diabetes Research | Lipoprotein-Associated Phospholipase A 2 Mass Level Is Increased in Elderly Subjects with Type 2 Diabetes Mellitus [Pubmed:24818163] |
| Metabolism. | Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes [Pubmed:25034387] |
| J Am Heart Assoc | Effect of Extended‐Release Niacin on High‐Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin‐Treated Patients [PubMed: 26374297] |
| Czecho-Slovak Dermatology / Cesko-Slovenska Dermatologie | V [Ebscohost] |
| Endocrinol Metab (Seoul). | Effect of Pitavastatin Treatment on ApoB-48 and Lp-PLA2?in Patients with Metabolic Syndrome: Substudy of PROspective Comparative Clinical Study Evaluating the Efficacy and Safety of PITavastatin in Patients with Metabolic Syndrome [pmc:PMC4803547] |
| Clin Pharmacol Ther.? | Effect of dipyridamole on myocardial reperfusion injury: A double‐blind randomized controlled trial in patients undergoing elective coronary artery bypass surgery [Pubmed:25773594] |
| Lipids in Health and Disease | Effect of intensive insulin treatment on plasma levels of lipoprotein-associated phospholipase A 2 and secretory phospholipase A 2 in patients with newly … [articles:10.1186] |
| Acta Endocrinologica | SERUM LIPOPROTEIN-ASSOCIATED PHOSPHOLIPASE A2 IN MALES WITH METABOLIC SYNDROME AND OBSTRUCTIVE SLEEP APNEA. [jrnl:1841098] |
| Biomarker for diagnosis of moyamoya disease [:] | |
| JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | Circulating fatty-acid binding-protein 4 levels predict CV events in patients after coronary interventions [Pubmed: 32859455] |
| chinese neurosurgical journal | Can admission lipoprotein-associated phospholipase A2 predict the symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage? [] |
